The company had planned to launch the generic version of Actos on August 17th, after a 2010 settlement with the Japanese drugmaker, Takeda Pharmaceuticals. Watson believes that the FDA improperly ...

Search for a state or federal candidate to see the donors and industries that support them. Ballot measures allow voters to vote directly on a law or policy change. Explore the ballot measures ...

David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold shares of the company amounting to $101,103. The transaction, which occurred on January 22 ...

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20mg. Sildenafil is the ...

Watson Pharmaceuticals Inc. (WPI) recently announced that the US Food and Drug Administration (FDA) approved the company’s generic version of Pfizer Inc.’s (PFE) oral contraceptive Lybrel.

This decision pertained to patent litigation brought by Cephalon and its wholly-owned subsidiary CIMA Labs, Inc., against Watson Pharmaceuticals ... biopharmaceutical company dedicated to ...